Overview

PK Study of YH22189 FDC Compared to Combination of Telmisartan/Amlodipine and Rosuvastatin

Status:
Terminated
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This is a Randomized, open-label, single-dose, 3-treatment, 3-period, 3-sequence crossover design.
Phase:
Phase 1
Details
Lead Sponsor:
Yuhan Corporation
Treatments:
Amlodipine
Rosuvastatin Calcium
Telmisartan
Telmisartan amlodipine combination